FIRST-INHUMAN STUDY OF SAFETY, PHARMACOKINETICS AND PHARMACODYNAMICS OF IRAK1/4 INHIBITOR R835 IN HEALTHY SUBJECTS

被引：2
|
作者：
Yan, L. [1 ]
Tong, S. [1 ]
Absalom, A. [2 ]
Daas, I. D. [3 ]
Park, G. [1 ]
Taylor, V. [1 ]
Chow, D. [1 ]
Lee, M. [1 ]
Zheng, H. [1 ]
Chow, A. [1 ]
机构：
[1] Rigel Pharmaceut Inc, San Francisco, CA USA
[2] Univ Med Ctr Groningen, Groningen, Netherlands
[3] QPS Netherlands BV, Groningen, Netherlands
来源：
ANNALS OF THE RHEUMATIC DISEASES | 2020年 / 79卷
关键词：
D O I：
10.1136/annrheumdis-2020-eular.4590
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
THU0219
引用
收藏
页码：332 / 332
页数：1
相关论文
共 50 条
  • [1] PRECLINICAL EFFICACY OF R835, A NOVEL IRAK1/4 DUAL INHIBITOR, IN RODENT MODELS OF JOINT INFLAMMATION
    Lamagna, C.
    Chan, M.
    Tai, E.
    Siu, S.
    Frances, R.
    Yi, S.
    Young, C.
    Markovtsov, V.
    Chen, Y.
    Chou, L.
    Park, G.
    Masuda, E.
    Taylor, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 86 - 86
  • [2] CELL-TYPE SPECIFIC REGULATION OF IL-1R SIGNALING BY R835, A DUAL IRAK1/4 INHIBITOR
    Braselmann, S.
    Tai, E.
    Frances, R.
    Young, C.
    Markovtsov, V.
    Masuda, E.
    Taylor, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 1327 - 1327
  • [3] TARGETING IRAK1 AND 4 SIGNALING WITH R835, A NOVEL ORAL SMALL MOLECULE INHIBITOR: A POTENTIAL NEW TREATMENT FOR SYSTEMIC LUPUS ERYTHEMATOSUS
    Lamagna, C.
    Chan, M.
    Bagos, A.
    Tai, E.
    Young, C.
    Chen, Y.
    Chou, L.
    Park, G.
    Masuda, E.
    Taylor, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 30 - 30
  • [4] R835, A NOVEL IRAK1/4 DUAL INHIBITOR IN CLINICAL DEVELOPMENT, BLOCKS TOLL-LIKE RECEPTOR 4 (TLR4) SIGNALING IN HUMAN AND MOUSE
    Lamagna, C.
    Gundel, C.
    Chan, M.
    Young, C.
    Braselmann, S.
    Frances, R.
    Yi, S.
    Chen, Y.
    Park, G.
    Chou, L.
    Masuda, E.
    Taylor, V.
    ANNALS OF THE RHEUMATIC DISEASES, 2020, 79 : 575 - 575
  • [5] A first in man study to evaluate the safety, pharmacokinetics and pharmacodynamics of RP7214, a dihydroorotate dehydrogenase inhibitor in healthy subjects
    Nair, Ajit
    Barde, Prajak J.
    Routhu, Kasi, V
    Viswanadha, Srikant
    Veeraraghavan, Sridhar
    Pak, Samuel
    Peterson, Jeffrey A.
    Vakkalanka, Swaroop
    BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2023, 89 (03) : 1127 - 1138
  • [6] Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of PF-06650833, a Novel, Potentially First-in-Class Inhibitor of Interleukin-1 Receptor Associated Kinase-4 (IRAK-4) in Healthy Subjects
    Danto, Spencer
    Shojaee, Negin
    Li, Cheryl
    Gilbert, Steven A.
    Singh, Ravi Shankar
    Manukyan, Zorayr
    Kilty, Iain
    ARTHRITIS & RHEUMATOLOGY, 2017, 69
  • [7] Pharmacokinetics, pharmacodynamics, and safety of izuforant, an H4R inhibitor, in healthy subjects: A phase I single and multiple ascending dose study
    Jin, Byung Hak
    Hong, Taegon
    Yoo, Byung Won
    Kim, Choon Ok
    Kim, Dasohm
    Kim, Youn Nam
    Park, Min Soo
    CTS-CLINICAL AND TRANSLATIONAL SCIENCE, 2024, 17 (10):
  • [8] Pharmacokinetics, pharmacodynamics and safety of CKD-519, a CETP inhibitor, in healthy subjects
    Kim, Hoon Ok
    Oh, Un Sil
    Choi, Chungam
    Kim, Yeonjoo
    Lee, Sera
    Kim, Semi
    Park, Min Soo
    DRUG DESIGN DEVELOPMENT AND THERAPY, 2016, 10 : 3763 - 3770
  • [9] STUDY DESIGN OF A PHASE I, PLACEBO-CONTROLLED, FIRST-INHUMAN TRIAL TO ASSESS SAFETY AND TOLERABILITY, IMMUNOGENICITY, AND PHARMACOKINETICS AND PHARMACODYNAMICS OF SINGLE ASCENDING DOSES OF THE ANTI-ADAMTS-5 NANOBODY®, M6495, IN HEALTHY MALE SUBJECTS
    Balchen, T.
    Strotmann, R.
    Bihlet, A. Reinstrup
    Sonne, J.
    Ladel, C.
    Moreau, F.
    Guehring, H.
    OSTEOARTHRITIS AND CARTILAGE, 2018, 26 : S276 - S277
  • [10] Safety, Pharmacokinetics, and Pharmacodynamics of the Autotaxin Inhibitor GLPG1690 in Healthy Subjects: Phase 1 Randomized Trials
    van der Aar, Ellen
    Desrivot, Julie
    Dupont, Sonia
    Heckmann, Bertrand
    Fieuw, Ann
    Stutvoet, Simone
    Fagard, Liesbeth
    Van de Wal, Karen
    Helmer, Eric
    JOURNAL OF CLINICAL PHARMACOLOGY, 2019, 59 (10): : 1366 - 1378
12345